首页> 外文期刊>Journal of cardiac failure >Novel Extracellular Matrix Biomarkers as Predictors of Adverse Outcome in Chronic Heart Failure: Association Between Biglycan and Response to Statin Therapy in the CORONA Trial
【24h】

Novel Extracellular Matrix Biomarkers as Predictors of Adverse Outcome in Chronic Heart Failure: Association Between Biglycan and Response to Statin Therapy in the CORONA Trial

机译:新型细胞外基质生物标志物作为慢性心力衰竭不良结果的预测因子:CORONA试验中双链糖蛋白和他汀类药物疗法反应之间的关联

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The extracellular matrix (ECM) plays an important role in left ventricular remodeling and progression of heart failure (HF). Biglycan and mimecan are ECM proteins that are abundantly expressed in cardiac tissue but have not been evaluated as prognostic markers in HF. We investigated their interaction with statin treatment and association with adverse outcome in chronic HF.
机译:背景:细胞外基质(ECM)在左心室重构和心力衰竭(HF)进展中起重要作用。 Biglycan和mimecan是ECM蛋白,在心脏组织中大量表达,但尚未被评估为HF的预后标志物。我们调查了他们与他汀类药物治疗的相互作用以及与慢性心衰不良反应的关系。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号